MAY 0 5 2009

Attorney's Docket No. Application Serial No. Form PTO-1449 GNE-0151-D2 10/644,875 INFORMATION DISCLOSURE STATEMENT Applicant(s) Ying-Fei Wei, et al. Filing Date: **Group Art Unit:** (use several sheets if necessary) August 21, 2003 1647 **U.S. PATENT DOCUMENTS** Examiner Ref. Date Document No. Class Subclass Filing Date Initials No. (if appropriate) FOREIGN PATENT DOCUMENTS Ref. Date Document No. Class Translation Examiner Name **Subclass** Initials No. YES NO 09/18/2003 WO 03/075855 A2 WIPO 1. 12/15/2005 WO 2005/117986 A2 WIPO 03/30/2006 WO 2006/034488 A2 WIPO 12/06/2007 WO 2007/140371 A2 WIPO 11/20/2008 WO 2008/141044 A2 WIPO OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Title Ref. Examiner Initials No. Junutula, et al., "ThioMabs: Improving Safety Abd Retaining Efficacy Of Antibody Drug Conjugates", AACR, Vol. 48, 6. pages 220-221, (2007) Lambert, et al., "Drug-Conjugates Monoclonal Antibodies For The Treatment Of Cancer", Current opinion in 7. pharmacology, Vol. 5, No. 5, pages 543-549, (2005) Mao, et al., "Tenb2 As A Therapeutic Antibody Drug Target For The Treatment Of Prostate Cancer", MCT, Vol. 6, No. 12, page 3356S, (2007)

1	EXAMINER:	DATE CONSIDERED:
	EAGINIVEIX.	own considerab.
ĺ		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).